Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ocular Therapeutix Inc OCUL

Healthcare
Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular... see more

Recent & Breaking News (NDAQ:OCUL)

Ocular Therapeutix Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Business Wire October 6, 2020

Ocular Therapeutix(TM) Announces First Patients Dosed in Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease

Business Wire September 29, 2020

Ocular Therapeutix(TM) Announces First Patient Dosed in Phase 3 Clinical Trial of DEXTENZA® for the Treatment of Post-Surgical Ocular Inflammation and Pain in Children

Business Wire September 10, 2020

Ocular Therapeutix(TM) Announces Successful Resolution of FDA Warning Letter Related to ReSure® Sealant

Business Wire September 8, 2020

Ocular Therapeutix Announces Third Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts

Business Wire September 4, 2020

Ocular Therapeutix(TM) to Present at Two Upcoming Investor Conferences

Business Wire September 3, 2020

Ocular Therapeutix(TM) Reports Second Quarter 2020 Financial Results and Business Update

Business Wire August 7, 2020

Ocular Therapeutix(TM) To Report Second Quarter 2020 Financial Results

Business Wire July 31, 2020

Ocular Therapeutix Announces Second Medicare Administrative Contractor to Establish New Published Physician Fee Schedule for Administration of Intracanalicular Inserts

Business Wire July 23, 2020

Ocular Therapeutix Presents at the 12th Annual Ophthalmology Innovation Summit (OIS)

Business Wire July 17, 2020

Ocular Therapeutix Announces Its First Published Physician Fee Schedule for Administration of Intracanalicular Inserts

Business Wire July 15, 2020

Ocular Therapeutix(TM) to Hold Virtual 2020 Annual Meeting Of Stockholders

Business Wire June 15, 2020

Ocular Therapeutix(TM) to Present Data at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Business Wire June 15, 2020

Ocular Therapeutix(TM) to Present at the 2020 Raymond James Human Health Innovation Conference

Business Wire June 10, 2020

Ocular Therapeutix(TM) to Present at the Jefferies Virtual Healthcare Conference

Business Wire May 29, 2020

Ocular Therapeutix(TM) Announces Pricing of Public Offering of Common Stock

Business Wire May 20, 2020

Ocular Therapeutix(TM) Announces Proposed Public Offering of Common Stock

Business Wire May 19, 2020

Ocular Therapeutix(TM) Announces First Patient Dosed in Phase 1 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease

Business Wire May 12, 2020

Ocular Therapeutix(TM) To Present New Data at the American Society of Cataract and Refractive Surgery (ASCRS) 2020 Virtual Annual Meeting

Business Wire May 11, 2020

Ocular Therapeutix(TM) Reports First Quarter 2020 Financial Results and Business Update

Business Wire May 8, 2020